Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About ACAD Interactive Breakdown Better Bets vs. ACAD Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

ACADIA Pharmaceuticals (ACAD)

Market Price (10/26/2025): $22.03 | Market Cap: $3.7 Bil
Sector: Health Care | Industry: Pharmaceuticals

ACADIA Pharmaceuticals (ACAD)

Market Price (10/26/2025): $22.03
Market Cap: $3.7 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.0%		 Weak multi-year price returns
2Y Excs Rtn is -61%, 3Y Excs Rtn is -43%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.0%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%
3 Weak multi-year price returns
2Y Excs Rtn is -61%, 3Y Excs Rtn is -43%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x

Market Valuation & Key Metrics

ACADS&P 500
REVENUE GROWTHGOOD
Rev LTM ($ Bil)1.0
Rev Chg Q9.3%6.4%
Rev Chg LTM14.4%5.3%
Rev Chg 3Y Avg27.9%5.4%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)0.1
CFO LTM ($ Bil)0.2
Net Inc LTM ($ Bil)0.2
Op Mgn LTM8.9%18.7%
CFO/Rev LTM18.4%20.5%
Net Inc Mgn21.8%12.7%
VALUATIONHIGH
P/S3.63.3
P/CFO19.716.1
P/FCF41.920.9
P/E16.624.0
STABILITYVERY GOOD
Debt/Equity0.020.21
Cash/Assets0.620.07

ACAD Stock

   
   
   
   
   
   
   

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
ACAD Return25%-56%-32%97%-41%20%-49%
Peers Return4%1%-1%-6%-2%19%13%
S&P 500 Return16%27%-19%24%23%15%110%

Monthly Win Rates [3]
ACAD Win Rate50%50%33%67%33%56% 
Peers Win Rate20%37%43%42%47%58% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
ACAD Max Drawdown-26%-70%-44%0%-54%-23% 
Peers Max Drawdown-21%-7%-18%-25%-14%-24% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, ARWR, ALKS, OGN, BGM. See ACAD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/24/2025 (YTD)

How Low Can It Go

Unique KeyEventACADS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-76.3%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven322.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-36.1%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven56.5%51.3%
2020 Covid PandemicTime to BreakevenTime to BreakevenNot Fully Recovered days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-67.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven205.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven389 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-95.4%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven2080.5%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1558 days1480 days

Compare to ACT, ARWR, ALKS, OGN, BGM


In The Past

ACADIA Pharmaceuticals's stock fell -76.3% during the 2022 Inflation Shock from a high on 1/7/2021. A -76.3% loss requires a 322.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About ACADIA Pharmaceuticals (ACAD)

Better Bets than ACADIA Pharmaceuticals (ACAD)

 ACADBetter Performance than ACAD
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM14.4%LLY (36.8%), CORT (25.7%), KNSA (56.2%), ALVO (82.6%), ANIP (38.7%)
Rev Chg 3Y Avg27.9%KNSA (96.3%), ALVO (150.9%), ANIP (44.2%), BCRX (40.4%), HROW (39.8%)
Op Mgn LTM8.9%LLY (43.0%), JNJ (26.2%), MRK (31.2%), PFE (26.1%), BMY (16.5%)
CFO/Rev LTM18.4%LLY (20.5%), JNJ (26.3%), MRK (29.1%), PFE (23.8%), BMY (30.0%)
FCF/Rev LTM8.7%JNJ (20.3%), MRK (23.1%), PFE (19.5%), BMY (27.5%), ZTS (23.6%)
Total Yield6.0%JNJ (8.1%), MRK (11.1%), PFE (12.8%), BMY (11.6%), ALKS (7.1%)
 ACADBetter Performance than ACAD
MetricValueAll Other Sectors
Rev Chg LTM14.4%NVDA (71.6%), MSFT (14.9%), META (19.4%), AVGO (28.0%), NFLX (15.4%)
Rev Chg 3Y Avg27.9%NVDA (92.0%), ANET (32.1%), CRWD (33.5%), HOOD (30.0%), DASH (28.4%)
Op Mgn LTM8.9%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM18.4%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM8.7%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), GOOGL (18.0%), META (30.7%)
Total Yield6.0%JPM (6.7%), XOM (9.7%), BABA (36.1%), BAC (6.9%), HD (6.2%)
 Best Bets In Health Care Sector
 ACADRPRX HALO CPRX LNTH PBH EW AVTR ILMN HCA THC
What You Pay           
P/E16.615.514.412.314.214.510.815.312.517.912.9
P/EBIT40.98.211.310.59.79.326.610.410.49.85.0
What You Get           
Rev Chg Q9.3%7.7%40.8%19.4%-4.1%-6.6%11.9%-1.1%-4.8%6.4%3.2%
Rev Chg LTM14.4%3.0%35.0%28.5%5.7%0.6%9.1%-2.3%-3.3%6.4%-1.1%
Rev Chg 3Y Avg27.9%0.8%35.5%49.9%34.3%0.8%3.0%-4.3%-3.0%6.6%2.7%
FCF/Rev 3Y Avg3.8%113.4%43.4%38.9%26.1%21.6%11.9%9.7%9.0%8.4%7.1%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1ACADIA Pharmaceuticals Earnings Notes  
2With ACADIA Pharmaceuticals Stock Down 13% In A Month, How Confident Are You?Return 
3Is The 20.2% Decline In ACADIA Pharmaceuticals (ACAD) Stock A Dip Buying Opportunity?Actionable 
4ACAD Dip Buy Analysis  
5ACADIA Pharmaceuticals Market PriceMarket Price 
6ACADIA Pharmaceuticals (ACAD) Operating Cash Flow ComparisonFinancials 
7ACADIA Pharmaceuticals (ACAD) Net Income ComparisonFinancials 
8ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $172 Bil), more valuable than Meta PlatformsNotification 
9ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta PlatformsNotification 
10ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta PlatformsNotification 
11ARTICLES  
12Down 20%, Is ACAD Stock A Buy Now? September 26th, 2025
13These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022? February 23rd, 2022
14Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month? January 5th, 2022
15These Healthcare Stocks Lagged This Year, But Might Offer Deep Value December 16th, 2021
16Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming October 25th, 2021
Title
0DASHBOARDS
1Down 20%, Is ACAD Stock A Buy Now?
2These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022?
3Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?
4These Healthcare Stocks Lagged This Year, But Might Offer Deep Value
5Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
6ARTICLES
7ACADIA Pharmaceuticals Earnings Notes
8With ACADIA Pharmaceuticals Stock Down 13% In A Month, How Confident Are You?
9Is The 20.2% Decline In ACADIA Pharmaceuticals (ACAD) Stock A Dip Buying Opportunity?
10ACAD Dip Buy Analysis
11ACADIA Pharmaceuticals Market Price
12ACADIA Pharmaceuticals (ACAD) Operating Cash Flow Comparison
13ACADIA Pharmaceuticals (ACAD) Net Income Comparison
14ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $172 Bil), more valuable than Meta Platforms
15ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta Platforms
16ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta Platforms

Trade Ideas

Select past ideas related to ACAD. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.5%3.5%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.4%6.4%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		19.5%19.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		17.1%17.1%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1498.4%344.0%
2PRAXPraxis Precision Medicines253.2%126.1%
3NVTSNavitas Semiconductor116.1%294.1%
4SNDKSanDisk97.4% 
5UAMYUnited States Antimony90.3%578.5%
6GRALGRAIL85.2%400.8%
7BALYBallys82.9%6.8%
8ORKAOruka Therapeutics81.1%40.5%
9INBXInhibrx Biosciences79.9%272.0%
10CIFRCipher Mining77.2%345.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1VGVenture Global-35.7% 
2PMIPicard Medical-35.3%8328.6%
3SOCSable Offshore-33.7%-41.7%
4FWRDForward Air-28.9%-39.0%
5FLYFirefly Aerospace-28.5% 
6ITGRInteger-28.4%-45.0%
7USNAUsana Health Sciences-26.5%-42.0%
8HTZHertz Global-26.3%41.5%
9RCReady Capital-25.1%-50.3%
10ULHUniversal Logistics-24.8%-61.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1VICRVicor57.5%87.2%
2INBXInhibrx Biosciences53.8%272.0%
3CLBCore Laboratories48.7%-2.4%
4BALYBallys46.2%6.8%
5MOFGMidWestOne Financial43.2%39.2%
6NUVBNuvation Bio42.2%82.3%
7CLOVClover Health Investments41.0%21.3%
8CELCCelcuity36.6%442.2%
9WGOWinnebago Industries33.6%-12.7%
10GTXGarrett Motion33.3%91.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-45.4%8328.6%
2ITGRInteger-30.4%-45.0%
3METCRamaco Resources-23.8%244.9%
4WRLDWorld Acceptance-18.6%25.6%
5ASMAvino Silver & Gold Mines-18.2%450.5%
6SESSES AI-17.6%15.5%
7SMPLSimply Good Foods-17.5%-48.0%
8TNGXTango Therapeutics-17.0%142.6%
9OKLOOklo-16.7%540.8%
10LENZLENZ Therapeutics-16.4%10.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for ACADIA Pharmaceuticals

Financials

ACADACTARWRALKSOGNBGMMedian
NameACADIA P.Enact Arrowhea.Alkermes Organon BGM  
Mkt Price22.0336.6638.5729.799.239.3425.91
Mkt Cap3.75.55.44.92.4-4.9
Rev LTM1,0191,2265731,5056,281-1,226
Op Inc LTM90--1083741,337-232
FCF LTM88701-18480482-480
FCF 3Y Avg45641-298322530-322
CFO LTM18870122521826-521
CFO 3Y Avg78641-175364872-364

Growth & Margins

ACADACTARWRALKSOGNBGMMedian
NameACADIA P.Enact Arrowhea.Alkermes Organon BGM  
Rev Chg LTM14.4%3.4%2,816.2%-0.2%-1.0%-3.4%
Rev Chg 3Y Avg27.9%3.7%908.8%9.2%-0.4%-9.2%
Rev Chg Q9.3%1.9%--2.1%-0.8%-0.6%
QoQ Delta Rev Chg LTM2.3%0.5%5.1%-0.6%-0.2%-0.5%
Op Mgn LTM8.9%--18.8%24.9%21.3%-15.1%
Op Mgn 3Y Avg-3.9%--958.1%22.3%22.2%-9.1%
QoQ Delta Op Mgn LTM-0.0%-2.9%-1.0%-0.9%--0.5%
CFO/Rev LTM18.4%57.1%3.8%34.6%13.2%-18.4%
CFO/Rev 3Y Avg7.1%54.5%-620.8%24.3%13.9%-13.9%
FCF/Rev LTM8.7%57.1%-3.1%31.9%7.7%-8.7%
FCF/Rev 3Y Avg3.8%54.5%-949.2%21.5%8.4%-8.4%

Valuation

ACADACTARWRALKSOGNBGMMedian
NameACADIA P.Enact Arrowhea.Alkermes Organon BGM  
Mkt Cap3.75.55.44.92.4-4.9
P/S3.64.59.43.30.4-3.6
P/EBIT40.96.0-71.411.72.0-6.0
P/E16.68.1-36.114.13.4-8.1
P/CFO19.77.8245.59.42.9-9.4
Total Yield6.0%14.4%-2.8%7.1%39.0%-7.1%
Dividend Yield0.0%2.1%0.0%0.0%9.6%-0.0%
FCF Yield 3Y Avg1.5%13.4%-8.8%7.1%13.3%-7.1%
D/E0.00.10.10.03.7-0.1
Net D/E-0.2-0.3-0.1-0.23.5--0.2

Returns

ACADACTARWRALKSOGNBGMMedian
NameACADIA P.Enact Arrowhea.Alkermes Organon BGM  
1M Rtn4.6%-6.2%15.9%6.8%-10.3%-8.1%-0.8%
3M Rtn-5.3%4.7%141.4%14.0%-10.1%-10.6%-0.3%
6M Rtn49.5%6.4%186.8%7.0%-24.6%-15.9%6.7%
12M Rtn53.6%8.2%89.1%14.2%-44.4%17.0%15.6%
3Y Rtn40.3%67.4%14.5%41.0%-58.3%-40.3%
1M Excs Rtn1.0%-8.1%17.2%7.0%-12.3%-11.1%-3.5%
3M Excs Rtn-8.9%-1.3%128.3%7.7%-14.2%-13.3%-5.1%
6M Excs Rtn26.6%-16.5%163.9%-15.9%-47.5%-38.8%-16.2%
12M Excs Rtn35.6%-12.0%70.4%-10.0%-61.1%5.2%-2.4%
3Y Excs Rtn-42.6%-7.6%-66.4%-40.6%-138.3%--42.6%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/8/20252/27/202511/7/20248/7/20245/9/20242/28/202411/3/20238/3/20235/8/20232/28/202311/3/2022
Key Financials Quarterly            
Total Revenue265244260250242206231212165118136131
Ebitda35221234332137-565-53-46-30
Operating Income3219732301535-583-54-46-31
Net Income271914433331746-651-43-42-27
EPS0.160.110.860.200.200.100.28-0.400.01-0.27-0.26-0.17
Key Financials TTM            
Total Revenue TTM1,019996958929891814726632551520517512
Ebitda TTM104102100125346-68-150-124-162-222-220
Operating Income TTM90888411223-5-73-154-127-164-224-222
Net Income TTM22222922612931-2-61-149-111-146-216-217
Growth Rates Quarterly            
Total Revenue Growth9.3%18.7%12.4%18.3%46.4%73.8%69.3%62.0%22.8%2.6%4.4%-0.7%
EBITDA Growth7.0%7.2%-66.6%161.0%587.2%139.0%180.3%-84.6%114.5%52.7%-3.3%-112.1%
Operating Income Growth6.4%26.8%-80.0%154.8%902.2%128.4%175.9%-87.2%109.0%52.6%-3.1%-101.7%
Net Income Growth-20.1%14.7%213.9%150.3%2897.2%138.5%209.8%-139.8%103.3%61.9%3.2%-88.0%
Margins Quarterly            
EBITDA Margin13.3%9.1%4.7%13.7%13.6%10.1%15.8%-26.5%2.9%-44.9%-33.4%-23.2%
Operating Income Margin12.2%7.9%2.7%12.6%12.6%7.4%15.1%-27.3%1.8%-45.2%-33.7%-23.6%
Net Income Margin10.1%7.8%55.4%13.1%13.8%8.0%19.8%-30.8%0.7%-36.3%-30.6%-20.8%
Cash & Debt            
Total Cash762682756565501471439346375403417437
Total Debt565652495860575759616263
Net Debt / (Cash)-706-626-704-516-443-411-382-289-317-342-355-374
Cash Flows Quarterly            
FCF from Operations64204063252985-598-18-24-1
Cash Flows TTM            
FCF from Operations TTM188149158203816417-93-34-56-114-113
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC3.8%2.3%1.1%4.4%4.5%1.9%5.6%-9.1%0.1%-8.4%-7.6%-5.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM3.3%3.3%3.3%4.4%0.6%-0.2%-3.0%-6.1%-5.1%-6.7%-9.3%-9.3%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
NUPLAZID549517484  
DAYBUE17700  
Product sales, net   442339
Total726517484442339


Price Behavior

ACAD Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta3.071.801.820.840.901.03
Up Beta3.362.802.110.550.690.97
Down Beta0.170.771.150.750.811.01
Up Capture22%86%148%156%145%100%
Bmk +ve Days13233574144420
Stock +ve Days9193261119349
Down Capture724%271%240%128%108%103%
Bmk -ve Days8192952107330
Stock -ve Days12233063127394

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity8,753,033
Short Interest: % Change Since 9302025-7.0%
Average Daily Volume2,170,142
Days-to-Cover Short Interest4.03
Basic Shares Quantity167,827,000
Short % of Basic Shares5.2%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20252.5%5.6%6.1%
5/7/202514.3%15.9%48.4%
2/26/20251.8%-4.8%-9.5%
11/6/20248.9%11.4%9.4%
8/6/2024-19.5%-16.6%-14.0%
5/8/2024-11.2%-11.7%-13.1%
2/27/2024-9.9%-9.7%-31.0%
11/2/20234.7%-4.3%-0.6%
...
SUMMARY STATS   
# Positive1058
# Negative121714
Median Positive3.7%11.4%9.9%
Median Negative-5.1%-4.8%-10.0%
Max Positive14.3%15.9%48.4%
Max Negative-19.5%-16.6%-46.6%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024807202410-Q 6/30/2024
3312024509202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231103202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023508202310-Q 3/31/2023
12312022228202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022809202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211109202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0GAROFALO ELIZABETH A.9032025Sell25.981,60041,560659,305Form
1Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER8192025Sell25.1822,000554,0241,010,590Form
2Brege Laura6052025Sell21.7814,446314,634328,769Form
3Kihara JamesPRINCIPAL ACCOUNTING OFFICER5192025Sell25.002,00050,000559,875Form
4Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER5192025Sell25.002,00050,0001,553,250Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.